The patents are valid till 2024
Suven Life Sciences has been granted a patent in India for a drug used for the treatment of neuro-degenerative diseases.
In a BSE filing, Suven Life said it has been granted ‘one product patent from India corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.’
The patents are valid till 2024, the company added.
Venkat Jasti, CEO, Suven Life said, “We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”
With these new patents, Suven has 20 granted patents from India.
“These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II,” Suven said.